Decheng Capital Management III (Cayman)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$42.1M	Hold	2,099,583	–	–	14.06%	2
2023 Q2	$59.2M	Buy	2,099,583 +275,000	+15%	+$6.6M	18.58%	2
2023 Q1	$31.4M	Hold	1,824,583	–	–	12.66%	2
2022 Q4	$36.7M	Hold	1,824,583	–	–	13.75%	2
2022 Q3	$39.5M	Hold	1,824,583	–	–	14.33%	2
2022 Q2	$51.3M	Buy	+1,824,583	New	+$48.3M	19.44%	1

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s ZNTL Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Zentalis Pharmaceuticals (ZNTL) position steady in Q3 2023 at 2,099,583 shares worth $42.1M. The position accounts for 14.06% of the portfolio, ranked #2.

Decheng Capital Management III (Cayman) first reported a position in ZNTL in Q2 2022 and has held it in 6 quarters since. The position peaked at $59.2M in Q2 2023. 137 funds tracked by Wall St. Rank hold ZNTL as of Q3 2023.

Decheng Capital Management III (Cayman) held 2,099,583 shares of Zentalis Pharmaceuticals worth $42.1M as of Q3 2023.
Decheng Capital Management III (Cayman) left its Zentalis Pharmaceuticals share count unchanged in Q3 2023.
Zentalis Pharmaceuticals made up 14.06% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #2 holding.
Decheng Capital Management III (Cayman) first reported a position in Zentalis Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Decheng Capital Management III (Cayman)'s Zentalis Pharmaceuticals position peaked at $59.2M in Q2 2023.
137 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.